These were some of the stocks making the largest moves in trading on Tuesday.
Check out the companies making headlines in midday trading. Eli Lilly — Shares added 5% after Eli Lilly, maker of the Mounjaro diabetes and weight loss drug, beat analysts' expectations for first-quarter adjusted earnings. The Indianapolis -based drugmaker also lifted its full-year guidance for adjusted earnings and revenue. 3M — Shares jumped 4% after the maker of industrial products and adhesives posted earnings of $2.39 per share on revenue of $7.
Current-quarter revenue is expected to come in higher than analysts anticipate. Amkor Technology — The semiconductor packaging company climbed nearly 7% after earnings and revenue topped analyst estimates. Earnings of 24 cents per share on $1.37 billion in revenue exceeded consensus forecasts of 11 cents and $1.36 billion, according to FactSet. Second quarter earnings and revenue guidance also topped expectations. Sysco — The wholesale restaurant supplier slipped 2.
Currency Pegging Central Banking Monetary Policy Bank Of Japan European Central Bank Economic Growth Economic Stimulus Economic Outlook Economic Policy Inflation Interest Rates Federal Reserve Bank Japan Government Breaking News: Markets Money Markets Forex Markets Federal Reserve System Japanese Yen Bitcoin Cryptocurrency U.S. Dollar Currency Markets Bitcoin/USD Coin Metrics GBP/USD EUR/USD DXY US Dollar Currency Index USD/JPY Eli Lilly And Co Earnings Dividends Indianapolis Business News
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly, 3M, PayPal rise premarket; Coca-Cola, Tesla, McDonald's fallEli Lilly, 3M, PayPal rise premarket; Coca-Cola, Tesla, McDonald's fall
Read more »
Stocks making the biggest premarket moves: Eli Lilly, Travelers, United Airlines, Alcoa and moreThese are the stocks posting the largest moves in the premarket.
Read more »
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Read more »
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Read more »
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »